Sanofi: Time not right to sell off beauty unit

September 1997
WWD: Women's Wear Daily;9/8/1997, Vol. 174 Issue 48, p4
Trade Publication
Focuses on pharmaceuticals and beauty products company, Sanofi's executive vice president for administration and finance, Jean-Paul Leon's issuance of a statement to clarify French business newspapers report that the company is planning to sell off its beauty division. Overview on Sanofi's businesses and financial performance for the first half of 1997.


Related Articles

  • Beauty sales at Sanofi decline 2%.  // WWD: Women's Wear Daily;4/14/1995, Vol. 169 Issue 72, p9 

    Reports on the decline in sales of Sanofi SA's beauty products and fragrances during the first quarter of 1995.

  • Third alternative. Horton, Kathleen // Pharmaceutical Executive;Aug97, Vol. 17 Issue 8, p92 

    Reports on Sanofi SA's acquisition of the rights to market Hyalgan (hyaluronate) in the United States.

  • Sanofi operating net drops 35% in fragrance, beauty areas in '94.  // WWD: Women's Wear Daily;3/16/1995, Vol. 169 Issue 51, p24 

    Reports on the financial performance of Sanofi in 1994. Operating profits from fragrance and beauty products; Sales; Earnings.

  • Sanofi beauty sales off 4.3% in 4th quarter.  // WWD: Women's Wear Daily;2/11/1997, Vol. 173 Issue 28, p9 

    Reports on the decline in Sanofi SA beauty sector's sales in the fourth quarter of 1996. Expected increase in earnings as compared to year-ago results; Growth in Yves Saint Laurent's Opium lines for men and women; Increase in total company sales.

  • Back in black.  // WWD: Women's Wear Daily;9/1/1995, Vol. 170 Issue 43, p5 

    Reports on Sanofi SA's breakeven in operating profit for its perfumes and beauty division in the first half of 1995. Improvement in earnings due to a restructuring of its distribution and sale of unprofitable brands such as Stendhal, Perry Ellis and Geoffrey Beene.

  • Sanofi sales up 3.6 percent.  // WWD: Women's Wear Daily;7/22/1994, Vol. 168 Issue 15, p7 

    Reports that Sanofi's sales for its fragrance and beauty division reached $369.4 million for the first six months of 1994. Comparison with 1993 sales; Brand gainers.

  • Sanofi sales grow 10% in first 9 months of '97.  // WWD: Women's Wear Daily;11/5/1997, Vol. 174 Issue 87, p18 

    Reports on sales growth of French pharmaceuticals and beauty giant Sanofi for the first nine months of 1997.

  • French drug maker Sanofi has begun construction on its new Algerian facility.  // African Business News;10/2/2013, p8 

    The article reports that construction on the new Algerian facility of French drug maker Sanofi has been started.

  • Dronedarone Tablets (Multaq®). Elliott, William T.; Chan, James // Internal Medicine Alert;9/15/2009, Vol. 31 Issue 17, p133 

    The article offers information on the nature, dosage, potential physiological benefits and hazards, and clinical implications of the Dronedarone drug tablets, marketed as Multaq® by Sanofi-Aventis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics